On 13th April NHS England published the initial 2022/23 budgets of the 42 Integrated Care Boards (ICBs) expected to go live from 1st July 2022, subject to legislative approval. The...
Read More
NHS England published its 2022/23 National Tariff Payment System on 31st March 2022, a day before the new NHS financial year. The system provides guidance for the continued running of...
Read More
Our experts in health economics, value communication, design and digital discussed how to craft digital payer value communication tools to meet the needs of internal stakeholders, including market access teams...
Read More
The National Institute for Health and Care Excellence (NICE) has published updated manuals for methods, processes and topic selection for Health Technology Assessments (HTA). This includes changes to how NICE...
Read More
Pharma and Medtech professionals put questions to our panel of NHS associates as we reflected on the operational, structural, and clinical challenges the NHS has faced in 2021 and how...
Read More
In this webinar, we explored the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe. Orphan medicines and rare disease treatments are...
Read More
Following over 25 years in the pharmaceutical industry engaging directly with NHS decision-makers, and having spent several years working for the NHS as Head of Engagement, Karen Cooper recently joined...
Read More
How can the NHS address health inequalities through innovation? How can new health technologies help improve population health? How can Pharma, Medtech and the wider life sciences industry support the...
Read More
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In the final part of...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In Part 3 of the...
Read More
